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Pneumococcal conjugate vaccine (PCV) efficacy is lower for 
noninvasive pneumonia than invasive disease. In this study, 
participants were immunized with 13-valent PCV (PCV13) or 
hepatitis A  vaccine (control). Bronchoalveolar lavage samples 
were taken between 2 and 6 months and serum at 4 and 7 weeks 
postvaccination. In the lung, anti-capsular immunoglobulin G 
(IgG) levels were higher in the PCV13 group compared to con-
trols for all serotypes, except 3 and 6B. Systemically, IgG levels 
were elevated in the PCV13 group at 4 weeks for all serotypes, 
except serotype 3.  IgG in bronchoalveolar lavage and serum 
positively correlated for nearly all serotypes. PCV13 shows 
poor immunogenicity to serotype 3, implying lack of protective 
efficacy.
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Colonization of the human nasopharynx with Streptococcus 
pneumoniae (pneumococcus [Spn]) is a frequent and immun-
izing event, but local/distal tissue invasion leads to a spectrum 
of diseases, including pneumonia. Community-acquired pneu-
monia (CAP) is a leading cause of death across all economic 
settings [1].
The licensed 7-, 10-, and 13-valent pneumococcal conjugate 
vaccines (PCV7, PCV10, and PCV13, respectively) are designed 
to elicit anti-capsular immune responses to some of the most 
prevalent serotypes causing disease. Currently either PCV10 
or PCV13 is included in childhood immunization programs 
of many countries, whereas a pneumococcal polysaccharide 
vaccine (PPSV23) is more commonly recommended for older 
adults and high-risk groups. Despite vaccinations, 2 PCV13-
included serotypes, 3 and 19A, have continued to be detected 
in colonization studies in fully PCV13-vaccinated children [2]. 
Serotype 3 is especially important in adults, where it makes up 
a significant amount of remaining pneumococcal disease, the 
majority of which is CAP [3]. PCV13 efficacy against CAP has 
been reported to be lower compared to invasive pneumococcal 
disease (IPD), with a study finding 45% vaccine efficacy for a 
first episode of vaccine-type nonbacteremic, noninvasive CAP, 
compared to 75% for IPD [4]. Assessment of the efficacy of 
PCVs against CAP is more complicated than IPD, due to diag-
nostic challenges, lower specificity of the endpoint measuring 
efficacy to CAP, and presence of other respiratory pathogens 
causing CAP. Estimated lower vaccine efficacy could be the re-
sult of reduced humoral responses to PCV13 in the lung mu-
cosa, as failure of local immunoglobulin production in the lung 
has been associated with increased nosocomial pneumonia in 
ventilated patients [5]. Herein, we described the anti–capsular 
polysaccharide (CPS) immunoglobulin G (IgG) responses in 
the lung lining fluid of healthy adults in response to PCV13 
vaccination and compared the levels of anti-CPS IgG to 6B in-
duced by experimental nasal pneumococcal colonization or 
immunization.
METHODS
Healthy, nonsmoking participants aged 18–50  years were en-
rolled into a randomized controlled trial previously described 
[6]. Ethical approval was given by the Northwest-Liverpool 
East Research Ethics Committee reference number 12/
NW/0873. Participants were randomized to receive the PCV13 
(Prevenar-13, Pfizer; n = 49) or hepatitis A  (HepA) vaccine 
(Avaxim, Sanofi Pasteur MSD; n = 50). Serum samples were col-
lected at baseline and at 4 weeks and 7 weeks postvaccination. 
Five weeks following vaccination, participants were inoculated 
intranasally with live pneumococcus, serotype 6B, as part of an 
experimental human pneumococcal challenge study to test effi-
cacy of the vaccine against nasal colonization [7].
A subset (n = 19 [HepA, n = 10 and PCV13, n  =  9]) con-
sented to research bronchoscopy, and this subset is the focus 
of this article (Supplementary Table 1). Bronchoalveolar lavage 
(BAL) samples were collected at a singular time point between 
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Figure 1. A, Levels of immunoglobulin G to capsular polysaccharide (anti-CPS IgG) for 12 pneumococcal serotypes (PS) in bronchoalveolar lavage (BAL) fluid collected 
between 2 and 6 months postvaccination (Post-V) with either 13-valent pneumococcal conjugate vaccine (PCV13; n = 9) or hepatitis A vaccine (HepA; n = 10). Each dot rep-
resents an individual. Error bars depict medians with interquartile range (IQR). Mann–Whitney test was used. *P < .05, **P < .01. B, From left to right: Levels of IgG to CPS 
of Streptococcus pneumoniae (Spn) 6B measured in the BAL fluid of HepA/Spn+ (n = 8), PCV13/Spn– (n = 8), Spn+ (n = 31), and Spn– (n = 32) up to 6 months after pneumo-
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2 and 6  months postvaccination (Supplementary Figure 1A), 
using a procedure previously described [8]. In addition, a subset 
of nonvaccinated (PCV13 or PPSV23) participants (n = 63), 
enrolled in different experimental human pneumococcal chal-
lenge studies (15/NW/0146, 14/NW/1460), were stratified 
based on carriage status to assess the effect of nasopharyngeal 
pneumococcal colonization on lung mucosa.
IgG levels to capsular polysaccharides of all vaccine serotypes 
were measured in both serum and BAL samples using the World 
Health Organization (WHO) standardized enzyme-linked im-
munosorbent assay (ELISA) method, as previously described 
[9]. IgG to 6A was not measured due to cross-reactivity with 6B 
[10]. In brief, ELISA plates were coated with 5 μg/mL of each 
purified CPS (Statens Serum Institut). BAL supernatant was 
used undiluted, whereas serum samples were used in three 1:3 
serial dilutions, starting from 1:50. Antigen-specific antibodies 
were detected by goat anti-human IgG (1/4000; Fc-specific) al-
kaline phosphatase (Sigma). Optical density was measured at 
405 nm using FLUOstar Omega plate reader (BMG Labtech).
Multiplex opsonophagocytosis assays were performed in 
serum samples, using the WHO standard method, as previ-
ously described [11]. Three cassettes of pneumococcal bacteria, 
containing 4 pneumococcal serotypes each resistant to a dif-
ferent antibiotic (Supplementary Table 2) (covering all PCV13 
serotypes except serotype 3), were incubated with serial dilu-
tions of human serum, then further incubated with baby rabbit 
complement and HL-60 cells. Each well was spotted onto 4 
blood agar plates and each plate was overlaid with agar con-
taining an antibiotic before overnight incubation, allowing only 
the correspondingly resistant pneumococcal strain to grow. 
Opsonophagocytic activity was calculated by determining the 
concentration of serum at which 50% of bacteria were killed.
Statistical Analysis
Antibody titers from control and PCV13-immunized subjects were 
compared using the Mann–Whitney U test when 2 groups were 
compared. Friedman test with Dunn multiple comparisons test was 
performed when 3 groups were compared. The serum and BAL IgG 
titers were converted to a log10 base and analyzed for correlation 
with linear regression by the Pearson correlation coefficient using 
the statistical software R and Prism 8. Significance was set at P < .05.
RESULTS
PCV13 Elicits Antibody Responses in the Lung Lining Fluid Against All 
Serotypes, Except Serotype 3
To investigate whether PCV13 elicits antibody responses in the 
lung of vaccinated subjects, we used research bronchoscopy 
to sample the human lung within 6 months after vaccine ad-
ministration. Levels of anti-CPS IgG in BAL were statistically 
significantly higher in the PCV13 group (n = 9) compared to 
the control group (n = 10) for all vaccine antigens, except sero-
type 3 and 6B (Figure 1A). The highest fold difference in BAL 
IgG levels between the 2 groups was measured for serotype 23F, 
whereas the lowest significant difference was measured for se-
rotype 19F (Supplementary Table 2). Anti-CPS IgG to 23F and 
19F was, respectively, 8.4- and 1.8-fold higher in the PCV13 
group compared to controls (median, 8.4-fold [interquartile 
range {IQR}, 2.8- to 12.6-fold] and 1.8-fold [IQR, 1.4- to 5.1-
fold]). Both HepA and PCV13 subjects were inoculated with 
Spn 6B at 5 weeks postvaccination, which resulted in 8/10 (80%) 
and 1/9 (11%) carriage in the HepA and PCV groups, respec-
tively (Supplementary Table 1). Titers of BAL IgG to CPS-6B 
between experimentally induced pneumococcal carriers (Spn+, 
n = 8) in the control group and noncarriers (Spn–, n = 8) in the 
PCV13 group did not differ significantly (P = .32; Figure 1B). 
This boosting effect of nasopharyngeal pneumococcal coloni-
zation in the lung was also observed in a separate nonvaccinated 
cohort, where Spn carriers (n = 31) had 4.3-fold higher levels of 
IgG to CPS-6B in the BAL compared to noncarriers (n = 32) up 
to 6 months postcolonization (median, 3.51 [IQR, 1.19–11.74] 
in Spn+ vs 0.81 [IQR, 0.62–1.11] in Spn–) (Figure 1B).
In the analysis of the IgG titers with time, levels of anti-
capsular IgG in BAL were sustained at relatively higher levels in 
PCV13-immunized subjects compared to the controls for up to 
4 months postvaccination for most serotypes, although they de-
creased over time (Supplementary Figure 1B). A steeper drop in 
antibody levels was observed in serotypes that had some of the 
lowest fold rises compared to the control vaccinated subjects 
(9V, 19A, 19F) (Supplementary Figure 1B).
In blood, baseline levels of anti-CPS IgG increased for all 
measured vaccine antigens at 4 weeks postvaccination in 
PCV13 subjects, except serotype 3 (1.25 [IQR, 1.06–1.51] 
fold-increase; P = .129) (Table 1, Figure 1C). Serum anti-CPS 
IgG to nearly all serotypes, except serotype 3, also increased 
from baseline to 7 weeks postvaccination. Raised antibody 
titers decreased from 4 weeks to 7 weeks postvaccination for 
all the vaccine antigens. This drop was most profound for 
anti-CPS IgG to 19A, which decreased by 32% over this time 
period (median, 9.06 [IQR, 3.40–20.02] µg/mL at 4 weeks vs 
6.17 [IQR, 3.15–14.10] µg/mL at 7 weeks; P = .019). Likewise, 
in PCV13 subjects, opsonophagocytic killing increased at 4 
weeks postvaccination compared to baseline for most vaccine 
antigens, with killing capacity declining over time (7 weeks 
postvaccination) (Supplementary Figure 1C).
of serum anti-CPS IgG from baseline (prevaccination) at 4 and 7 weeks after vaccination measured against 12 vaccine serotypes. Boxplots depict median and IQR. Dashed 
line represents FC equal to 1. Friedman test following Dunn multiple comparison test was used. ****P < .0001. D, Correlation of anti-CPS IgG levels in serum at 7 weeks 
after vaccination with the paired anti-CPS IgG levels detected in BAL sample the day of bronchoscopy. Spearman correlation was used and linear regression line with 95% 
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Correlation of anti-CPS IgG titers in BAL and paired serum 
samples at 7 weeks postvaccination in the PCV group demon-
strated a positive association for all serotypes, except 9V, with a 
moderate strength of association for most serotypes (Figure 1D).
DISCUSSION
This study demonstrates that vaccination with PCV13 elicits 
IgG responses to vaccine antigens not only systemically but 
also in the lung mucosa and that pneumococcal colonization 
with Spn 6B may have a boosting effect in the lung, similar to 
that induced by intramuscular immunization. Postvaccination, 
lung IgG levels against the vaccine antigens, although waning 
over time, were still higher in the PCV13 group for some sero-
types compared to control counterparts for up to 4  months. 
In serum, PCV13 elicited robust serotype-dependent IgG re-
sponses. Heightened serum IgG titers began to decline after 4 
weeks postvaccination, although they did not differ statistically 
between 4 and 7 weeks postvaccination. This phenomenon was 
observed for most measured vaccine serotypes, except sero-
type 3, in which PCV13 did not induce antibody responses ei-
ther systemically or in the lung mucosa, implying diminished 
immunogenicity.
Many studies have reported reduced PCV13 ability to elicit 
antibody responses against serotype 3 in serum [3] and have 
suggested that higher IgG concentrations may be required to 
protect against this serotype [12]. As a result, there is some de-
bate regarding the effectiveness of PCV13 against serotype 3 
disease. PCV13’s reduced immunogenicity to serotype 3 may 
reflect the high circulation of serotype 3 throughout the PCV13 
implementation. Clearly, serotype 3 differs from other sero-
types, and its ability to evade current vaccine strategies is of con-
cern. On the other hand, PCV13 induced robust IgG responses 
in blood and lung for serotype 19A. Some possible factors con-
tributing to serotype 19A emergence are high rates of 19A car-
riage, penicillin nonsusceptibility, and capsular switching [13].
Overall, our blood and BAL findings are in agreement with 
data from Malawi, whereby vaccination with PCV7, which in-
duces antibody responses to serotypes 4, 6B, 9V, 14, 18C, 19F, 
and 23F, significantly increased capsular specific IgG to 4 sero-
types (6B, 14, 19F, and 23F) in serum and BAL of both human 
immunodeficiency virus–positive and –negative Malawian 
adults [5]. In this study, no significant difference was observed 
between antibody responses to Spn 6B in BAL between PCV13 
and control-vaccinated subjects, as both groups were chal-
lenged with 6B at 5 weeks after vaccination. The pneumococcal 
challenge resulted in disproportionally higher pneumococcal 
colonization rates in the control group (80% in control vs 11% 
in the PCV group) and elicited similar levels of lung antibodies 
to CPS of 6B in the colonized, control vaccinees compared to 
noncolonized, PCV13 vaccinees. As opposed to a study of in-
haled delivery of PPSV23 [14], nasopharyngeal pneumococcal 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































/jid/advance-article/doi/10.1093/infdis/jiab331/6308071 by guest on 05 August 2021
 BRIEF REPORT • jid 2021:XX (XX XXXX) • 5
of colonized subjects. This is consistent with previous work 
from our group, which has shown that human pneumococcal 
colonization has an immunogenic effect in the lung by seeding 
the lung mucosa with pneumococcal-specific CD4+ T cells 
[15]. In this study, cellular responses, such as tissue resident 
polysaccharide-specific B cells, following PCV13 vaccination 
were not measured. However, as memory B cells are an impor-
tant aspect of lung immune defenses, future studies are needed 
to focus on the role of resident B cells in the lung in response 
to vaccination and the local IgG production—knowledge that 
will contribute to better understand the relationship of PCVs 
and the lower vaccine efficacy witnessed against CAP compared 
to IPD.
Some of the limitations of this study are the small sample 
size and the difference in timing of sample collection between 
serum and BAL samples, which may have affected the strength 
of correlation between these 2 sites. Despite this, the study 
shows an appropriate response to PCV13 in lung fluid up to 
4  months postvaccination. Also, the positive association be-
tween systemic and lung IgG suggests antibody diffusion from 
blood to mucosa, providing assistance to the site of infection. 
These findings work against the notion that poor humoral re-
sponses at the lung mucosa play a role in reduced vaccine effi-
cacy for most serotypes, except serotype 3. Our findings imply 
that discrepancies in vaccine efficacy against pneumonia could 
be due to several other factors, such as viral coinfection causing 
CAP, diminished lung resident cell function during such 
coinfections, or challenges to ascertain pneumonia etiology. On 
the other hand, lack of immunogenicity against serotype 3 sup-
ports numerous data on reduced vaccine efficacy for this sero-
type. Additionally, the study encourages the idea of developing 
a live attenuated pneumococcal vaccine for inhaled delivery for 
the prevention of pneumonia.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
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